Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $99
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Edwards Lifesciences (EW) and raises the price target from $94 to $99.
April 26, 2024 | 6:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Overweight rating on Edwards Lifesciences and raises the price target from $94 to $99.
The upgrade in the price target by a reputable analyst like Larry Biegelsen suggests a positive outlook on the company's future performance. This is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100